Why Intuitive Surgical Is a Strong Buy as Robotic Surgery Adoption Accelerates
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Robotic surgery’s market leader has had a rough start to 2026, but our model sees the pullback as an opportunity. Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) trades at $482.22 after a 14.86% year-to-date decline, even as Q1 procedure growth and da Vinci 5 adoption continue to accelerate.
Our 24/7 Wall St. price target for Intuitive Surgical is $615.93, implying meaningful upside over the next 12 months.
24/7 Wall St. Price Target Summary
| Metric | Value |
|---|---|
| Current Price | $482.22 |
| 24/7 Wall St. Price Target | $615.93 |
| Upside | 27.73% |
| Recommendation | BUY |
| Confidence | 90% |
A Sell-Off That Outran the Fundamentals
Shares are down 5.1% over the past year and sit roughly 20% below the 52-week high of $603.88. The stock has stabilized recently, gaining 2.77% over the past week, helped by a strong Q1 2026 print on April 21.
Intuitive delivered non-GAAP EPS of $2.50 versus a $2.11 consensus, and revenue of $2.77 billion, up 22.96% YoY. Operating income jumped 47.95%, and the company placed 431 da Vinci systems, including 232 da Vinci 5 units. That marks four straight EPS beats.
The Case for $649 and Higher
Bulls point to da Vinci 5, which now has an installed base of 1,500 systems and is driving U.S. utilization growth of 4%, higher than Xi. CEO Dave Rosa noted “da Vinci 5 utilization continues to exceed that of da Vinci Xi”.
Single Port procedures grew 68% YoY, and Ion procedures climbed 39%, supported by a Mayo Clinic study showing 79% diagnostic yield in lung lesion biopsy. Our bull case price is $649.08, a 34.6% total return.

The Risks Worth Watching
The bear case starts with valuation. ISRG trades at a P/E of 58 and EV/EBITDA of 42. Procedure growth is decelerating to 13.5% to 15.5% in 2026, down from 18% in 2025.
Tariffs on Mexico, Germany, and China sourcing add roughly 1% revenue drag, GLP-1 adoption pulled bariatrics down 10%, and China faces policy-driven pricing pressure.
Insider activity has been net selling, though it appears largely tied to scheduled vesting. Bulls would counter that gross margin actually expanded to 67.8%, and da Vinci 5 contribution margins are now comparable with Xi. Our bear case price is $546.67, still above today’s price.
Our Take on Intuitive Surgical Here
My read: the 24/7 Wall St. price target of $615.93 with 90% confidence reflects a high-quality compounder trading at a 20% discount to its 52-week high while still posting 23% revenue growth. The bull thesis stays intact if da Vinci 5 placements stay above 230 per quarter and tariff drag holds at 1%. The setup weakens if procedure growth slips below 13% or hospital capex tightens materially.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $615.93 |
| 2030 | $981.22 |
Outer-year projections for 2027-2029 are not separately modeled; our framework anchors on the 12-month target and a 2030 endpoint, assuming mid-teens procedure growth, modest multiple compression, and continued buybacks. Significant variance could come from da Vinci 5 international ramp, telesurgery commercialization, or tariff escalation.
Contact [email protected] for any questions or corrections.





